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W e l c o m et ot h i ss p e c i a li s s u eo fP P A Rr e s e a r c hd e d i c a t e d
to “PPARs in Eye Biology and Disease.” PPARs are well
known to regulate the expression of genes involved in lipid
and glucose metabolism. Very recently, these transcription
factors have been demonstrated to modulate proliferative,
inﬂammatory,andoxidativestressresponses,includingthose
that happen in the eye. We have collected a comprehensive
group of review papers that are focused on discussing the
relationships of PPARs with choroidal neovascularization,
inﬂammation, and redox balance, as well as perspective
therapeutic potentials of PPAR modulators in eye diseases.
Angiogenesis is an important element of normal devel-
opment and neovascularization which occurs normally in
wound healing. However, neoangiogenesis is unfortunately
also associated with various pathological ocular conditions
including corneal neovascularization secondary to graft
rejection and traumatic, chemical, and infectious insults;
diabetic complications in both the anterior and posterior
segments; retinoproliferative disease secondary to vaso-occ-
lusive events; as well as choroidal neovascularization asso-
ciated with trauma, high myopia, genetic disease, and age-
related macular degeneration (AMD). Of these, AMD is
currently the leading cause of blindness in the developed
world. As such, much eﬀort and expense is and has
been invested in understanding and seeking cures for this
devastating condition. Although there is little direct evidence
linking PPAR action to AMD, there is a growing body of
literature demonstrating that PPARs may be involved in
various chemical pathways associated with AMD. In this
issue, three papers authored by respected experts in the ﬁeld
are presented which review what we now know about the
relationship between the 3 PPAR isoforms, α, β,a n dδ,a n d
ocular angiogenesis with emphasis on AMD. Bishop-Bailey
has reviewed PPARβ/δ-mediated angiogenesis in the context
of ocular disorders. Gehlbach et al. have brieﬂy discussed the
PPAR-α ligands as potential therapeutic agents for wet AMD.
Chan et al. have comprehensively described PPARs with the
development of AMD. There now appears to be ample data
in the peer-reviewed literature to encourage further study
of the link between PPARs and AMD, and investigate the
therapeutic potential of PPARs. In addition, an authoritative
fourth paper authored by Pershadsingh is also oﬀered to
address PPARγ agonists as potential therapeutics for non-
AMD proliferative retinopathies.
Inﬂammatory signaling participates in the development
of diﬀerent forms of eye diseases. Inﬂammatory injury happ-
ensundertheconditionsinwhichpathoangiogenicsignaling
isactivatedinacuteinﬂammatoryresponses;chronicinﬂam-
mation is triggered by oxidative stress in diabetic retinopathy
and atrophic AMD. The majority of reports documented in
the literature support an anti-inﬂammatory role of PPARs,
in particular PPARγ, by blocking the release of inﬂamma-
tory mediators from activated immune cells in vitro and
dampening inﬂammation in animal models. Minghetti et al.
have explored the roles of PPARγ in microglial cell functions
and therapeutic potentials of PPARγ ligands on ocular
diseases such as AMD, diabetic retinopathy, autoimmune
uveitis, and optic neuritis. Yanagi has evaluated the role of
PPARγ in the breakdown of blood-retinal barrier, providing
strong evidence that targeting PPARγ would be beneﬁcial
to diabetic retinopathy via maintaining the integrity of
blood-retinal barrier. Phipps et al. have extensively reviewed
the literature regarding the role of lymphocytes in thyroid
eye disease-related inﬂammation, oﬀering PPARγ ligands
as a therapeutic approach via inhibition of inﬂammatory
signaling in activated lymphocytes and ﬁbroblasts.
The potential regulation of redox balance by PPARs in
theeyehasbeenrecentlysuggestedandmayconstituteanew,2 PPAR Research
excitingresearchﬁeldoverthenextfewyears.Phagocytosisof
tips of rod outer segments’ selectively upregulates expression
ofPPARγ inretinalpigmentepithelial(RPE)cells,suggesting
thatPPARγ activationmightdealwithoxidativestressduring
RPE cell phagocytosis. Oxidative stress is a major risk factor
causing RPE cell degeneration since RPE cells are exposed to
high levels of free radicals due to phagocytosis of oxidized
photoreceptor outer segments, intense light irradiation, and
high oxygen consumption in the macular area. PPARγ
ligands protect a variety of cell types from oxidative stress
injury in vitro, including retinal cells, though no in vivo
data are available yet. Chang et al. have brieﬂy reviewed the
cytoprotective eﬀects of an endogenous PPARγ agonist, 15d-
PGJ2, on oxidative stress-induced RPE cell death.
PPARs are emerging as potential targets for drugs that
might be used in the treatment of ocular diseases in which
PPAR activities play a key role in disease pathology. It is our
hope that this special issue will serve as a seed stimulating
broad interests to pursue therapeutic avenues of PPARs
in eye diseases. The outcomes of such investigations will
undoubtedly shed light on the roles of PPARs in eye diseases
and possibly identify new roles of PPARs in the etiology of
eye diseases.
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